We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Despite intense lobbying by business interests, including pharmaceutical company representatives, it appears unlikely that the current research and development (R&D) tax credit for corporations will be extended by Congress before it expires June 30, according to knowledgeable sources.
Sen. John Kerry (D-Mass.) has embraced the reimportation of prescription drugs and negotiated drug prices under Medicare as part of his presidential campaign platform, while accusing the Bush administration of selling out to pharmaceutical manufacturers.
The Republican chairman and the ranking Democrat on the House Government Reform Committee have introduced legislation designed to curb the growing number of Rx drugs sold over the internet without a valid prescription.
A bill pending in the House is intended to fix a patent law problem that has had a chilling effect on collaborative research between industry and universities, but the legislation could produce some unintended problems of its own, according to the Biotechnology Industry Organization (BIO).
Unless major changes are made, Canadian generic drugmakers say they are unlikely to take advantage of a proposed drug export law that would let them break patents on brand drugs sent to poor countries facing health emergencies such as AIDS, malaria and tuberculosis.
Legislation pending in the House intended to fix a patent law problem, which has had a chilling effect on collaborative research between industry and universities, could produce some unintended problems of its own, according to the Biotechnology Industry Organization (BIO).
HHS Secretary Tommy Thompson must turn over all cost estimates associated with the new prescription drug benefit added to the Medicare program by Feb. 17, House Democratic leaders demanded last week.
House Democratic leaders are demanding HHS Secretary Tommy Thompson provide to them by Feb. 17 all cost estimates associated with the new prescription drug benefit added to the Medicare program.